Clicks: 280
ID: 147121
2013
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #42 of 475 articles by views in communications in computer and information science

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 475 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
ObjectiveTo assess the prevalence and the profile of adverse events (AE) of natalizumab in patients with multiple sclerosis (MS).MethodsData collection from neurologists attending to patients with MS at specialized units in Brazil.ResultsData from 103 patients attending the infusion centers of 16 MS units in 9 Brazilian states were included in the study. The total number of infusions was 1,042. Seventy-nine patients (76.7%) did not present any AE. Twenty-four patients (23.3%) presented only mild AE. There were three major AE, including two deaths. These three occurrences, although not necessarily being drug-related, must be taken into consideration.ConclusionThe profile of AEs for natalizumab shows that 97% of patients have none or only mild AE. However, still due to safety worries, the use of this medication should be restricted to MS units under the care of specialized neurologists.
ObjetivoAvaliar a prevalência e o perfil dos eventos adversos (EA) por natalizumabe em pacientes com esclerose múltipla (EM).MétodosColeta de dados fornecidos por neurologistas de unidades especializadas em EM no Brasil.ResultadosNo estudo, foram incluídos dados de 103 pacientes em tratamento em centros de infusão de 16 unidades de EM em 9 estados brasileiros. O número total de infusões foi 1.042. Setenta e nove pacientes (76,7%) não apresentaram nenhum EA. Vinte e quatro pacientes (23,3%) apresentaram apenas EA leves. Foram relatados três importantes EA, incluindo duas mortes. Embora não necessariamente ligadas à droga, estas EA devem ser levadas em consideração.ConclusãoO perfil de EA para natalizumabe mostrou que em 97% dos pacientes não houve EA ou houve apenas EA leves. No entanto, dadas as preocupações com segurança da droga, o uso deste medicamento deve continuar restrito às unidades de EM sob os cuidados de neurologistas especializados.
Reference Key
fragoso2013arquivos Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Yára Dadalti Fragoso;Soniza Vieira Alves-Leon;Walter Oleschko Arruda;Margarete de Jesus Carvalho;Elizabeth Regina Comini-Frota;Éber Castro Corrêa;Maria Lucia Brito Ferreira;Paulo Diniz da Gama;Sidney Gomes;Marcus Vinicius Magno Gonçalves;Damacio Ramón Kaimen-Maciel;Maria Fernanda Mendes;Rogerio Rizo Morales;Andre Muniz;Pedro Rippel Salgado;Heloisa Helena Ruocco;Livia Brito Bezerra de Albuquerque;Joseph Bruno Bidin Brooks;Letícia Fêzer;Sergio Georgetto;Josiane Lopes;Fabíola Rachid Malfetano;Isabella D'Andrea Meira;Celso Luis Silva Oliveira;Francisco Tomaz Meneses de Oliveira;Fabiana Safanelli;Massaco Satomi
Journal communications in computer and information science
Year 2013
DOI
DOI not found
URL
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2013000300137
Keywords
multiple sclerosis adverse events antibodies natalizumab neuropsychiatry biological psychiatry anticorpos monoclonaisneurosciences

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.